Has Hubert Pan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,522 in general payments to Hubert Pan, MD across 4 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Hubert Pan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Hubert Pan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Hubert Pan, MD

Radiation Oncology · Sacramento, CANPI 1699017368

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,205 of the $2,522 with a category attached, or 87.4%. AstraZeneca accounts for 87.4% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $2,205 and has fallen 92.4% since, to $168 in 2025.

$2,522in general payments, 2019–2025

Across 4 payments — averaging $630.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$2K
Monteris Medical Corporation$294
Siemens Medical Solutions USA, Inc.$23

What the payments were for

Consulting fees$2,20587%
Food & beverage$31713%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	1	$2,205
Monteris Medical Corporation	2	$294
Siemens Medical Solutions USA, Inc.	1	$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

IMFINZI$2,205
Neuroblate$294

How this compares

$2,522 in reported general payments places this provider in the 75th percentile of 627 radiation oncology providers in California.

See all radiation oncology providers in California →

Medicare billing

Part B allowed, 2024

$1,123,744

Medicare patients

343

Services billed

4,496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	20	$386
Lidocaine Hcl ViscousLidocaine Hcl	18	$237

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Sacramento

Rakesh PatelLos Gatos$1.3M
Amir LavafPalm Springs$411K
Albert ChangLos Angeles$290K
Arya AminiDuarte$265K
Rizwan NuraniApple Valley$220K
Drew MoghanakiLos Angeles$183K
Jyoti MayadevSan Diego$170K
Percy LeeIrvine$125K
Felix FengSan Francisco$99K
Hyun KimDuarte$97K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →